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Purpose: Combination verteporfin photodynamic therapy (vPDT) and antivascular endothelial 
growth factor (anti-VEGF) therapy may decrease the need for injections while maintaining 
visual acuity in exudative age-related macular degeneration. This pilot study was designed to 
determine the threshold fluence dose of vPDT (the dose required to demonstrate an effect on 
choroidal perfusion) combined with ranibizumab.
Methods: Seven patients were randomized to sham vPDT (two patients), 20% fluence vPDT 
(two patients), or 40% fluence vPDT (three patients) in combination with three-monthly intrav-
itreal 0.5 mg ranibizumab injections. Intravitreal ranibizumab was reinjected if disease activity 
was seen on fluorescein angiography, optical coherence tomography, or clinical examination. 
Indocyanine green-determined choroidal hypoperfusion was graded in a masked fashion.
Results: Patients with 20% vPDT had mild hypoperfusion defects at seven days that resolved 
by week 4 (threshold dose); patients with 40% fluence vPDT had marked hypoperfusion at 
seven days that persisted as long as 12 months. Recruitment was stopped after limited efficacy 
was observed. One patient with 20% fluence vPDT lost 19 letters at one year; no other patient 
lost or gained .10 letters. Central retinal thickness decreased in six of seven patients, but 
ranibizumab injections did not decrease.
Conclusion: This pilot study shows that the threshold fluence dose of vPDT (when combined 
with ranibizumab) is approximately 20% standard fluence, and that mild and transient choroidal 
hypoperfusion can occur. Forty percent fluence vPDT causes a more prolonged and striking 
hypoperfusion. Despite hypoperfusion, no decrease in visual acuity or injections required was 
noted, suggesting that even higher fluence levels of vPDT may be necessary to decrease the 
number of anti-VEGF injections.
Keywords: neovascular age-related macular degeneration, choroidal hypoperfusion, threshold 
dose, verteporfin photodynamic therapy
Introduction
Age-related macular degeneration (AMD) is the most common cause of legal blindness 
in the elderly in the Western world, and the prevalence of AMD is expected to increase 
by more than 50% by the year 2020.1 There are two forms of AMD, ie, nonexudative 
and exudative. The exudative form, defined by the growth of a choroidal neovascular 
membrane (CNVM) and a subsequent increase in vascular permeability, is present in 
20% of patients, and accounts for 90% of severe vision loss in patients with AMD.2
Verteporfin (Visudyne®; QLT Ophthalmics, Inc., Menlo Park, CA, USA) photodynamic 
therapy (vPDT) is a therapy introduced in the late 1990s as a treatment for neovascular Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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AMD. vPDT causes selective vascular occlusion of CNVM 
vessels, and the initial fluence levels and dose-escalation 
response of verteporfin PDT were determined in animal 
models.3–5 Because the initial dose response curves of vPDT 
were completed in primates, the actual threshold and toxic 
doses of vPDT in humans were never accurately determined 
(Andrew Strong, PhD, QLT Pharmaceuticals, personal com-
munication, 2008). This fluence dose was then used in the 
pivotal Treatment of age-related macular degeneration with 
photodynamic therapy and Verteporfin in photodynamic therapy 
trials, leading to its Food and Drug Administration (FDA) 
approval as the first available drug for treatment of exudative 
AMD.6,7 While most patients receiving vPDT still lost vision, 
the treatment helped stabilize visual acuity and decreased lesion 
activity compared with sham treatment. Subsequent vPDT trials 
examined reduced (50%) fluence levels in an attempt to avoid 
choroidal hypoperfusion and the 4%–6% incidence of acute 
vision loss associated with vPDT, and several of these trials 
described a trend toward better visual outcomes.8
Recently, intravitreal agents (ranibizumab and beva-
cizumab) have supplanted vPDT as primary therapy for 
neovascular AMD. These drugs bind and inactivate vascular 
endothelial growth factor (VEGF) and substantially improve 
visual acuity when delivered as repeated intravitreal   injections.9 
Intravitreal anti-VEGF therapy with ranibizumab (Lucentis®; 
Genentech USA, Inc., San Francisco, CA, USA), an antihuman 
VEGF affinity-matured antibody fragment, was the first agent 
to show an increase in mean best corrected visual acuity at 
the 12-month time point in patients with exudative AMD. The 
ANCHOR (anti-VEGF antibody for the treatment of predomi-
nantly classic choroidal neovascularization [CNV] in AMD) 
trial demonstrated that monthly ranibizumab therapy produces 
significant gains in visual acuity compared with vPDT for pre-
dominantly classic subfoveal CNVM secondary to exudative 
macular degeneration, while MARINA (minimally classic/
occult trial of the anti-VEGF antibody ranibizumab) showed 
similar improvements in vision for minimally classic or occult 
CNVM treated with ranibizumab versus sham injections.10,11
Despite encouraging clinical results with anti-VEGF 
therapies (with either FDA-approved ranibizumab or the 
related agent, bevacizumab), most patients require repeated 
intravitreal injections at regular intervals to maintain initial 
visual acuity gains.12,13 Therapeutic approaches targeting 
different components of the neovascular pathophysiology in 
AMD have predominantly combined vPDT with anti-VEGF 
injections. This theoretically could decrease the need for 
indefinite intravitreal anti-VEGF injections while   maintaining 
the visual acuity gains that were seen in the monthly Lucentis 
therapy trials. As the fluence level of light   activation was 
empirically determined in the vPDT   trials, a lower level of 
light fluence may be equally effective in combination with an 
anti-VEGF agent with less potential vPDT-related choroidal 
hypoperfusion damage. The LUV (Lucentis® Utilizing Visu-
dyne®) study was designed to determine the threshold-dose 
fluence of vPDT when used in combination with intravitreal 
anti-VEGF therapy injections (ranibizumab), and to deter-
mine the minimum fluence dose in vPDT therapy that results 
in choroidal hypoperfusion.
Methods
LUV was a Phase IV comparative study evaluating the use of 
combination therapy with intravitreal ranibizumab and vPDT 
compared with intravitreal ranibizumab alone in patients with 
exudative AMD. In this single-site trial, approved by the 
Institutional Review Board, seven patients with naïve CNV 
secondary to exudative AMD were randomized at the time of 
entry into the study to sham vPDT (two patients), 20% fluence 
vPDT (two patients), or 40% fluence vPDT (three patients). 
Inclusion criteria were age $ 55 years, visual acuity between 
20/32 and 20/320 by ETDRS (Early Treatment Diabetic 
Retinopathy Study) refraction, and subfoveal neovascular 
membrane of any subtype confirmed by fluorescein angiog-
raphy and/or indocyanine green fluorescein angiography.
Patients received standard dosages of verteporfin (6 mg/m2 
body surface area) with reduced fluence (light dose of 10 J/
cm2 at an irradiance of 120 mW/cm2 for 20% fluence and 
20 J/cm2 at an irradiance of 240 mW/cm2 for 40% fluence) 
delivered by diode laser over 83 seconds on day 0 of the 
study. On the same day, 75 minutes prior to vPDT, all patients 
received concomitant induction with the first of three-monthly 
intravitreal injections of 0.5 mg ranibizumab.
Patients underwent ETDRS-standardized trial-frame refrac-
tions at 4 m, clinical examination, and optical coherence tomogra-
phy, at baseline and every follow-up visit. Fluorescein angiography 
and indocyanine green fluorescein angiography were performed at 
day 0, day 1, week 1, and months 1, 3, 6, and 9, and 12. Retreat-
ment with ranibizumab was given at each monthly visit (after the 
empiric three-monthly induction doses) if any evidence of active 
CNV was seen on clinical examination, qualitative-based optical 
coherence tomography findings, or fluorescein angiography.14 
Indocyanine green fluorescein angiography choroidal hypoperfu-
sion was graded in a masked fashion.
Results
After obtaining Institutional Review Board approval, seven 
patients were recruited for the study (seven males, aged Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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66–80 years) and six had follow-up through to 12 months 
(one patient died at month 5). Despite the initial study proto-
col, indocyanine green fluorescein angiography could not be 
obtained at all intended intervals due to a national shortage of 
indocyanine green that began in early 2007. By the end of the 
study, 70% of protocol indocyanine green fluorescein angiog-
raphy had been performed, and the lack of indocyanine green 
fluorescein angiography at certain intervals did not impact our 
final study results or conclusions. Median EDTRS refracted 
visual acuity at baseline was 20/32 in the sham group, 20/40 
with 20% fluence, and 20/32 with 40% fluence (Table 1). 
One patient in the sham group had 1+ nuclear sclerosis, one 
patient in the 40% fluence group had 2+ nuclear sclerosis, 
and the other five patients in the study were pseudophakic; 
there were no other media opacities. Central retinal thickness 
(CRT), as measured by optical coherence tomography (Stratus 
III OCT; Carl Zeiss, Dublin, CA) at baseline, was 268 in the 
sham group, 252 in the 20% fluence group, and 298 in the 
40% fluence group. By the end of the study, there were no 
adverse ocular or systemic safety events attributable to the use 
of vPDT, intravitreal ranibizumab, or their combined use.
One patient (patient 3) in the 20% fluence arm lost 
19 letters at one year. On clinical examination, fluorescein 
angiogram, and indocyanine green testing, the CNVM 
increased markedly in size and exudation despite treatment. 
No other patient in any arm lost or gained .10 letters at 
one year by ETDRS refracted visual acuity (Table 1 and 
Figure 1). CRT decreased in every patient by the end of the 
study, except in patient 3, who had a mean CRT at one year 
of 239, 292, and 215, respectively (Figure 2). The number 
of intravitreal ranibizumab treatments did not differ signifi-
cantly by study group, because patients in the sham vPDT 
arm required an average of 7.5 injections in 12 months versus 
8.0 injections in the 20% fluence vPDT group and seven 
injections in the 40% fluence vPDT group.
Choroidal hypoperfusion was graded in a masked fashion, 
and was most readily seen in the early phase of indocyanine 
green fluorescein angiography around the 3–5-minute time 
frame. No patient receiving sham vPDT had any evidence 
of choroidal hypoperfusion on indocyanine green angiogra-
phy at baseline or at any time during follow-up (Figure 3). 
Patients with 20% fluence vPDT had mild vPDT-related 
hypoperfusion defects that appeared by week one and mostly 
resolved by week 4 (Figure 4), while patients with 40% 
fluence vPDT had marked hypoperfusion that appeared by 
one week and persisted even up to 12 months (Figure 5).
Discussion
vPDT was developed to treat patients with subfoveal CNV 
due to AMD, pathologic myopia, and ocular histoplasmosis 
syndrome, by reducing leakage of blood and fluid from the 
neovascular endothelium of the CNV .6–8 Photodynamically-
damaged endothelium releases procoagulant and vasoactive 
factors through the lipo-oxygenase pathway (via leukot-
rienes) and cyclo-oxygenase pathway (via eicosanoids, such 
as thromboxane). These factors result in platelet aggrega-
tion, fibrin clot formation, and vasoconstriction, leading 
to vascular occlusion.15,16 Standard treatment involves a 
10-minute intravenous infusion of verteporfin (6 mg/m2 
body surface area), followed 15 minutes after the start of the 
infusion by the application of 50 J/cm2 light (600 mW/cm2 
for 83 seconds) to the eye.
Selectivity of verteporfin for neovascular tissues was 
attributed to its uptake via low-density lipoprotein (LDL) 
receptors and subsequent accumulation due to increased 
expression of LDL receptors on rapidly proliferating cells.17 
Despite its relative selectivity for CNV, standard fluence 
vPDT is associated with choroidal hypoperfusion that 
appears most intensely at one week and can persist for many 
months.18–20 This is seen more dramatically with indocyanine 
green fluorescein angiography, where the indocyanine green 
molecule is bound by albumin and retained mostly within the 
vessels, demonstrating that vPDT occludes choriocapillary 
vessels. Patients treated with standard fluence vPDT also 
Table 1 Patient demographics and results of ETDRS visual acuity and central retinal thickness
Patient Age Gender Eye vPDT fluence VA (day 0) CRT 0 VA (12 months) CRT 12 Injections (n)
1 66 M Os 0 20/32-1 269 20/32 237 8
2 80 M Os 0 20/32 266 20/32 241 7
3 77 M OD 0.2 20/63 271 20/160 383 11
4 79 M OD 0.2 20/32 232 20/32 201 5
5 76 M Os 0.4 20/40+3 327 20/40 220 7
6 77 M OD 0.4 20/32 269 20/50 209 7
7 77 M OD 0.4 20/125 374 * * 4
Note: *Patient 7 died at month 5 of the study.
Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity; CRT, central retinal thickness; vPDT, verteporﬁn photodynamic therapy.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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have an approximate 4% risk of severe vision loss in the short 
term after treatment, which is probably related to occlusion 
of blood supply to the central macula (choriocapillaris).
The rationale behind combination therapy for exudative 
AMD is to sustain improvements in visual acuity and angio-
graphic outcomes with fewer treatments, by   utilizing both vaso-
occlusive and antiangiogenic approaches.   Vascular occlusion 
with vPDT has been shown to break down the vascular barrier, 
stimulating angiogenesis and VEGF expression.21,22 This VEGF 
expression often causes exacerbation of retinal edema imme-
diately following vPDT treatment. Reduced fluence vPDT 
combined with intravitreal ranibizumab may minimize the 
effects of choroidal hypoperfusion and dampen the upregulated 
expression of VEGF and inflammatory mediators.22,23
Several reports have shown a reduced rate of potential dam-
age to collateral structures and trends towards improved out-
comes when using vPDT with half-standard fluence (300 mW/
cm2, a light dose of 25 J/cm2) as monotherapy8 or in combination 
with intravitreal triamcinolone acetonide.24,25 Twelve-month 
results of the Lucentis monotherapy versus Lucentis + Visudyne 
in the treatment of naïve patients with Neovascular Age Related 
Macular Degeneration (DENALI) study recently reported 
that combination therapy of half-standard fluence vPDT with 
ranibizumab led to visual outcomes that were not noninferior 
to ranibizumab monthly monotherapy; after an initial loading 
dose, the combination arms also required fewer injections of 
ranibizumab over the remainder of the study.26 With reduced flu-
ence, the delivery of light photons becomes the rate-determining 
step in the photochemical reaction.   Assuming that there is more 
accumulation of verteporfin in the CNV because of its higher 
concentration of LDL receptors, even lower fluence levels of 
vPDT may accentuate selective treatment in the CNV and lessen 
effects in the choriocapillaries and pigment epithelial cells.
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Figure 1 Results of logMAR BCVA over the 12 months of the study. Patient 3 
(20% vPDT fluence) lost 19 letters at one year, but no other patient in any arm lost 
or gained >10 letters at one year by ETDRS refracted visual acuity.
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Figure 2 Results of OCT central retinal thickness over the 12 months of the study. 
Central retinal thickness decreased in every patient by the end of the study except 
in patient 3. At baseline CRT was 268 in the sham group, 252 in the 20% fluence 
group, and 298 in the 40% fluence group, and at one year CRT was 239, 292, and 
215 respectively.
Figure 3 Early and late ICG of patient 2 (0% fluence vPDT). There is no evidence 
of choroidal hypoperfusion at any time point.  Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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In our study, choroidal hypoperfusion related to vPDT 
demonstrated on indocyanine green fluorescein angiography was 
mild, with 20% fluence vPDT. This hypoperfusion was transient 
and was not demonstrable after one month and may represent the 
threshold-dose fluence level. The threshold dose of a drug effect is 
the lowest dose that demonstrates any effect on the organ or organ-
ism being treated. For most beneficial drugs, optimum effects 
are found at doses slightly higher than the threshold dose, while 
toxicity may occur at even higher levels of drug. At 40% fluence 
levels, choroidal hypoperfusion was significant in all patients, 
presenting by one week after treatment, and persisting for as long 
as 12 months. One patient in this group had 2+ nuclear sclerosis, 
meaning that the effective fluence could be even lower than 40% 
fluence. Despite this evidence of a dose-related effect of vPDT on 
the choroidal vasculature, there did not seem to be any significant 
decrease in visual acuity outcomes, central retinal thickness 
measurements, or in the number of ranibizumab injections 
required when compared across the different treatment groups.
Figure 4 Early and late ICG of patient 4 (20% fluence vPDT). By day 7 after vPDT, 
there is a mild but deﬁnitive area of choroidal hypoperfusion in the area of treatment 
(yellow arrows). By one month, this defect has resolved.
Figure 5 Early and late ICG of patient 5 (40% fluence vPDT). As early as day 1 after 
vPDT, there is an area of superior choroidal hypoperfusion (red arrows) that becomes 
more pronounced by day 7. This ﬁnding persists through month 9 of the study.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Many studies have described choroidal hypoperfusion 
following vPDT, but the relationship with functional impair-
ment remains inconclusive. A study showing minimal 
choroidal hypoperfusion with reduced fluence vPDT versus 
significant hypoperfusion with standard vPDT indicated 
the differences in hypoperfusion were not correlated with 
short-term clinical outcomes, and that lesion size increased 
even more in the reduced fluence group.27 A report of even 
more extensive and prolonged hypoperfusion when vPDT 
is combined with intravitreal ranibizumab did not see any 
negative effect on visual acuity, and the authors postulated 
that persistent inactivation of CNV and slow recanalization 
may outweigh the harm from choroidal hypoperfusion.20 
Impaired perfusion may also still be compatible with good 
retinal function, because potential damage from oxidative 
radicals is limited, and neuronal or retinal tissue may be 
capable of increasing oxygen extraction rates under these 
conditions.28,29
In the current study, hypoperfusion of the choroid was dem-
onstrated, even with fluences much lower than what is clinically 
used or has been previously described. Although recruitment 
for the study was limited and prohibits the formation of any 
significant conclusions from the small number of patients, our 
findings imply that the vascular occlusion with vPDT may be 
less selective than what has been previously thought. It also sug-
gests that this occlusion in the choriocapillaris demonstrated by 
indocyanine green may be necessary for effective vPDT treat-
ment. It is encouraging that despite the choroidal hypoperfusion, 
there were no instances of immediate vision loss.
The LUV study examined only the lowest fluence vPDT 
levels, because the goal was to determine the threshold-dose 
fluence level of vPDT combined with intravitreal anti-VEGF 
therapy. It is possible that the threshold-dose fluence level 
of vPDT would be higher when it is not used with an agent 
that eliminates macular edema as effectively as ranibizumab. 
Because most pharmaceutical agents achieve their maximum 
efficacy at doses higher than the threshold dose, our pilot 
study suggests that a higher fluence level (more than 20% 
standard fluence) will probably be necessary to reduce the 
amount of concomitant anti-VEGF therapy. Data from the 
DENALI study, using 50% fluence compared with standard 
fluence in combination with anti-VEGF therapy, show that a 
fluence level significantly above the threshold dose (but still 
much lower than standard fluence) may produce noninferior 
visual outcomes compared with monthly ranibizumab, while 
simultaneously requiring fewer injections.26 Further stud-
ies would be beneficial to confirm these results, because 
profound choroidal hypoperfusion seen at higher fluence 
levels may decrease the amount of anti-VEGF injections 
required while not compromising gains in visual acuity.
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